Zhang S et al. - The current meta-analysis revealed that the use of ipilimumab was associated with an increased risk of treatment-related mortality.

Methods
The literature was searched for prospective trials that randomly assigned patients to ipilimumab treatment with or without concurrent therapy.

Results
5775 patients with solid tumours included in 12 RCTs were analyzed.
The pooled incidence of fatal adverse events (FAEs) for patients treated with ipilimumab was 1.13% compared with 0.22% in the control arms.
Ipilimumab-associated FAEs were not different based on cancer type, treatment mode, control type, and ipilimumab dose, 
Ipilimumab was associated with an increased risk of fatal gastrointestinal toxicity (OR = 4.5).